Noninvasive Test of Cell-Free Methylated DNA Markers Shows High Sensitivity and Specificity in Detection of Nasopharyngeal Carcinoma (NPC); Early Study Results Presented at ASCO 2019 by Laboratory for Advanced Medicine (LAM)

(by Michael D. O’Neill, Editor & Publisher of BioQuick News, based on interview of, and materials provided by, Dr. Dhruvajyoti Roy)--One of the highly significant abstracts presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago (May 31-June 4) described impressive preliminary data on the liquid biopsy detection of nasopharyngeal carcinoma (NPC), which is one of the most prevalent malignancies in Southeast Asia, the Mediterranean, and the Arctic. Using a proprietary test of cell-free DNA methylation markers, the Laboratory for Advanced Medicine (LAM), headquartered in Irvine, California, showed preliminary data demonstrating high sensitivity and high specificity in the early detection of NPC using its DNA methylation test (the IvyGene test). The LAM study was conducted using samples obtained from 168 subjects, including 59 subjects diagnosed with NPC (Stages I to IV), 14 subjects diagnosed with benign nasopharyngeal disease and 43 healthy subjects. From the 59 subjects diagnosed with NPC, a total of 57 subjects were correctly identified (sensitivity of 97%), with little difference between the sensitivity of detecting Stage I to Stage IV NPC (range 92% to 100%). Additionally, for subjects diagnosed with other cancers, a total of 86% of subjects were correctly identified as negative for NPC. Finally, all 43 samples drawn from healthy donors and all 14 samples drawn from subjects diagnosed with benign nasopharyngeal disease were correctly identified as negative for NPC (combined specificity of 100%).
Login Or Register To Read Full Story